Related Experiment Video
Updated: Jul 23, 2026
10:36
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
10.5K
Interrogating Estrogen Signaling Pathways in Human ER-Positive Breast Cancer Cells Forming Bone Metastases in Mice
Julia N Cheng1, Jennifer B Frye2, Susan A Whitman2
1Cancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, AZ 85724, USA.
Endocrinology
|May 8, 2024
Summary
Estrogen signaling in ER+ breast cancer bone metastases is complex. Genomic ERα signaling drives osteolysis, but non-genomic pathways are crucial for metastatic progression in bone.
Area of Science:
- Oncology
- Endocrinology
- Skeletal Biology
Background:
- Breast cancer bone metastases (BMET) are predominantly osteolytic and common in estrogen receptor-positive (ER+) breast cancer.
- Estrogen (E2) promotes osteolysis in ER+ BMET via mechanisms independent of tumor proliferation, suggesting a direct link between ERα signaling and bone destruction.
- Understanding the specific roles of different estrogen receptor (ER) signaling pathways is critical for managing ER+ BMET.
Purpose of the Study:
- To investigate the role of genomic and non-genomic estrogen receptor signaling in mediating osteolytic activity in ER+ breast cancer bone metastases.
- To compare the effects of estrogen (E2) and a genomic-only ER agonist, estetrol (E4), on osteolytic progression in ER+ BMET models.
Main Methods:
- Utilized an in vitro bioassay measuring parathyroid hormone-related protein (PTHrP) secretion to screen ER and signaling pathway-specific ligands.
- Examined the necessity and sufficiency of genomic ERα signaling for PTHrP secretion in ER+ human breast cancer cells.
- Assessed the in vivo effects of estetrol (E4) on osteolytic ER+ BMET progression in a mouse model.
Main Results:
- Genomic ERα signaling was identified as essential and sufficient for estrogen-induced osteolytic PTHrP secretion.
- Estetrol (E4), a genomic-only ER agonist, showed pharmacologic effects on bone but did not support osteolytic BMET progression, unlike E2.
- These findings suggest a critical role for non-genomic ER signaling in ER+ metastatic progression within the bone microenvironment.
Conclusions:
- Targeting estrogen signaling to treat ER+ BMET requires a nuanced approach, considering both genomic and non-genomic pathways.
- Non-genomic ER signaling appears vital for ER+ breast cancer metastatic progression in bone.
- Further research is needed to fully elucidate the interplay between tumor and bone ER signaling in BMET.
